Article

Viral Load Rebound in Placebo and Nirmatrelvir-Ritonavir Treated COVID-19 Patients is not Associated with Recurrence of Severe Disease or Mutations

2022-06-21

Abstract excerpt

<title>Abstract</title> <p>Nirmatrelvir-ritonavir was developed for the treatment of COVID-19 and has shown efficacy in a Phase 2/3 study of high risk patients (EPIC-HR1). Monitoring for the emergence of viral resistance and recurrence of symptoms is a critical component of any antiviral drug development. As part of the study of viral resistance, a sub-analysis was conducted to examine viral load rebound (VLR) fo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 563bad03-0570-568f-adbf-c70b0f00128b
DOI: 10.21203/rs.3.rs-1720472/v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Viral Load Rebound in Placebo and Nirmatrelvir-Ritonavir Treated COVID-19 Patients is not Associated with Recurrence of Severe Disease or MutationsDOI 10.21203/rs.3.rs-1720472/v2Read

Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19).Semantic proximity Read

A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral reboundSemantic proximity Read

Emerging SARS-CoV-2 Resistance After Antiviral Treatment.Semantic proximity Read

Oral Nirmatrelvir and Severe Covid-19 Outcomes During the Omicron SurgeSemantic proximity Read

Rapid Relapse of Symptomatic Omicron SARS-CoV-2 Infection Following Early Suppression with Nirmatrelvir/RitonavirSemantic proximity Read

Real-world Use of Nirmatrelvir-Ritonavir in COVID-19 Outpatients During the Emergence of Omicron Variants BA.2/BA2.12.1Semantic proximity Read

Early combination of sotrovimab with nirmatrelvir/ritonavir or remdesivir is associated with low rate of persisting SARS CoV-2 infection in immunocompromised outpatients with mild-to-moderate COVID-19: a prospective single center studySemantic proximity Read

Nirmatrelvir/ritonavir and molnuipiravir in the treatment of mild/moderate COVID-19: results of a real-life studySemantic proximity Read

Doravirine Resistance Patterns Identified Through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials.Semantic proximity Read

Effect of oral nirmatrelvir on Long COVID symptoms: a case seriesSemantic proximity Read

Molnupiravir Compared to Nirmatrelvir/Ritonavir for COVID-19 in High-Risk Patients with Haematological Malignancy in Europe. A Matched-Paired Analysis from the Epicovideha RegistrySemantic proximity Read

Assessment of Nirmatrelvir-Ritonavir Effects on Acute and Post-Acute COVID-19 Illness in US Adolescents: Target Trial EmulationSemantic proximity Read